AQP4 and myeloid sarcoma: However, several immunomodulatory drugs that are used in MS were associated with exacerbations in AQP4-ab positive NMOSD patients, which shifted the therapeutic approaches towards selecting medications based on known mechanisms of action for NMOSD and its pathophysiological characteristics (13).